The exploding head syndrome.

M W Green

doi:10.1007/s11916-001-0043-9

Home/Archive/PubMed

PubMed · 11309216

The exploding head syndrome.

M W Green

View original source ↗Export metadata ↓

Abstract

This article reviews the features of an uncommon malady termed "the exploding head syndrome." Sufferers describe terrorizing attacks of a painless explosion within their head. Attacks tend to occur at the onset of sleep. The etiology of attacks is unknown, although they are considered to be benign. Treatment with clomipramine has been suggested, although most sufferers require only reassurance that the spells are benign in nature.

Explore related subjects

Clomipramine Headache Humans Perception Selective Serotonin Reuptake Inhibitors Syndrome Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M W Green. 2001. The exploding head syndrome.. https://doi.org/10.1007/s11916-001-0043-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.

Meta-analytic reviews of placebo-controlled studies for obsessive-compulsive disorder have found that clomipramine is more effective than drugs with more selective actions on serotonin reuptake, whereas in most direct comparisons, clomipramine's superiority has been less obvious. The authors used metaregression to identify sources of he-terogeneity in placebo-controlled trials of clomipramine, fluvoxamine, sertraline, and paroxetine. They evaluated such patient characteristics as age, gender, age of obsessive-compulsive disorder (OCD) onset, and baseline severity of OCD and depression, and such study characteristics as exclusion or inclusion criteria, length of single-blind prerandomization period, length of trial, number of subjects, and publication year. We found considerable heterogeneity across studies that was associated, in part, with publication year, length of single-blind prerandomization period, length of trial, and severity of patients' OCD. The apparent superiority of clomipramine persisted after controlling for these factors. The authors also confirmed previous reports that placebo response is higher in more recent studies. Meta-analyses can help characterize responders and nonresponders. The authors urge investigators to provide summaries of patient characteristics, especially baseline severity, age at onset, and duration of OCD, by patients' response.

Clomipramine↗

PubMed2000

On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?

OBJECTIVE: To examine the efficacy and tolerability of clomipramine compared with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive-compulsive disorder (OCD), bearing in mind the recent Expert Consensus Guidelines recommendation to use clomipramine after 2 to 3 failed SSRI trials. METHOD: The literature on the pharmacotherapy of OCD was critically examined. RESULTS: The available research evidence is not conclusive but suggests that clomipramine possesses greater anti-obsessional efficacy than do the SSRIs. In addition, when clomipramine is presented to patients in a positive way, and properly used in small initial doses with gradual increases, it seems to be tolerated as well as the SSRIs. CONCLUSION: Recently expressed opinions that clomipramine should be used to treat OCD after 2 to 3 failed SSRI trials are not supported by research evidence. Both clomipramine and the SSRIs may be used as first-line treatments for OCD.

Clomipramine↗

PubMed1999

Double-blindness procedure did not mask giving of medication in panic disorder.

BACKGROUND: The purpose of this study was to measure the degree to which patients and their treating physicians correctly guessed whether patients were on an active treatment (paroxetine or clomipramine) or pill-placebo, and whether correctness of these guesses was related to treatment outcome. METHODS: Ninety-five panic disorder patients, randomized to receive double-blind treatment with paroxetine, clomipramine or placebo for twelve weeks, were asked half-way through this period to classify treatment as active or placebo. Medical doctors were asked the same. RESULTS: Both patients and physicians guessed correctly to a degree much greater than would be expected by chance whether the patient was on an active treatment. Neither patients nor physicians were good at estimating correctly whether a patient was on a placebo. There was a trend approaching significance for patients on a placebo, whose physicians believed that they were on active treatment, to have a higher rating of symptom improvement than those patients who were correctly guessed to be on placebo. CONCLUSION: The 'double-blindness' procedure did not mask the giving of antidepressive medication in panic disorder. There is some evidence that physicians who incorrectly classify patients on a placebo as receiving active treatment relate this to better treatment outcome.

Clomipramine↗